Impact of Oral Antihyperglycemic Therapy on All-Cause Mortality Among Patients With Diabetes in the Veterans Health Administration
Open Access
- 1 July 2007
- journal article
- Published by American Diabetes Association in Diabetes Care
- Vol. 30 (7) , 1689-1693
- https://doi.org/10.2337/dc06-2272
Abstract
OBJECTIVE— The objective of this analysis was to evaluate the impact of several classes of oral antihyperglycemic therapy relative to sulfonylurea monotherapy on all-cause mortality among a cohort of patients with diabetes from the Veterans Health Administration (VHA).Keywords
This publication has 20 references indexed in Scilit:
- Reduced cardiovascular morbidity and mortality associated with metformin use in subjects with Type 2 diabetesDiabetic Medicine, 2005
- Who Has Diabetes? Best Estimates of Diabetes Prevalence in the Department of Veterans Affairs Based on Computerized Patient DataDiabetes Care, 2004
- All‐cause mortality in diabetic patients treated with combinations of sulfonylureas and biguanidesDiabetes/Metabolism Research and Reviews, 2003
- Oral antidiabetic treatment in patients with coronary disease: Time‐related increased mortality on combined glyburide/metformin therapy over a 7.7‐year follow‐upClinical Cardiology, 2001
- Increased mortality in Type II diabetic patients using sulphonylurea and metformin in combination: a population-based observational studyDiabetologia, 2000
- Metformin and Risk of Cardiovascular DiseaseCardiology, 1999
- Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33)The Lancet, 1998
- Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34)The Lancet, 1998
- Agreement Between Administrative Files and Written Medical RecordsMedical Care, 1998
- Inference and missing dataBiometrika, 1976